Free Trial
NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

Entero Therapeutics logo
$2.04 +0.01 (+0.49%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.04 +0.00 (+0.25%)
As of 08/22/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Entero Therapeutics Stock (NASDAQ:ENTO)

Key Stats

Today's Range
$2.02
$2.24
50-Day Range
$1.09
$2.16
52-Week Range
$0.84
$2.78
Volume
163,315 shs
Average Volume
5.23 million shs
Market Capitalization
$3.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENTO Stock News Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
Entero Therapeutics Inc ENTO
Entero Therapeutics Delays 10-K Filing
See More Headlines

ENTO Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $1.8660 at the beginning of the year. Since then, ENTO stock has increased by 9.3% and is now trading at $2.04.

Entero Therapeutics, Inc. (NASDAQ:ENTO) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.42) earnings per share (EPS) for the quarter.

Shares of Entero Therapeutics reverse split on Monday, August 18th 2025.A 1-3 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include CDT Equity (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

Last Earnings
8/14/2025
Today
8/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTO
Previous Symbol
NASDAQ:ENTO
CIK
1604191
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,063.82%
Return on Assets
-17.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.81
Quick Ratio
2.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.96) per share
Price / Book
-0.52

Miscellaneous

Outstanding Shares
1,590,000
Free Float
1,576,000
Market Cap
$3.24 million
Optionable
N/A
Beta
0.80
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ENTO) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners